Sernova

Sernova Corp.

Stock Exchange Listing
TSX(v): SVA.V


Tel: 1 (877) 299-4603
Tel: (519) 858-5184
Fax: (519) 858-5099
info@sernova.com



Business Development

Philip Toleikis
Tel: (604) 961-2939
info@sernova.com



Investor Relations

Ray Matthews
Ray Matthews & Associates, Inc.
Tel: (604) 818-7778
ray@raymatthews.ca



Address

Sernova Corp.
700 Collip Circle, Ste 114
London, ON
Canada N6G 4X8

    Corporate Strategy

    Sernova is committed to the development and clinical advancement of its products for chronic diseases using therapeutic cells transplanted into an implanted medical device, forming a natural environment promoting long term function of the therapeutic cells. The company’s management believes in building strong and long-lasting collaborations and partnerships that would lead to the rapid advancement of Sernova’s portfolio of products into the market, improving global health and bringing value to patients and society.




    Latest Video and Presentations


    Sernova Fact Sheet - / June 21, 2016 Open


    Sernova's 2016 Corporate Presentation - PDF Presentation / June 21, 2016 Open

    All Presentations →
    Cell Pouch System™

    Cell Pouch System™

    Sernova’s Cell Pouch System™ is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells. These therapeutic cells release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs.

    Read More…
    Sertolin™

    Sertolin™

    Sertolin™ provides an immune-protected local environment for transplanted therapeutic cells such as insulin producing islets by producing factors which modulate the local immune response. Sertolin™ may reduce or eliminate the need for immunosuppressant agents.

    Read More…
    Go Back

    Jeffrey Bacha

    Director - Board of Directors

    BSc, MBA


    Mr. Bacha holds a B.Sc. in Biophysics from the University of California and an M.B.A. from the Goizueta Business School at Emory University.

    Mr. Bacha brings 15 years of life sciences experience in the areas of operations, strategy and finance for biotechnology, pharmaceutical and medical device companies in Canada, the United States and Europe.

    Mr. Bacha is currently Executive Vice President, Corporate Affairs and Chief Operating Officer of Clera Inc., a company developing new medicines to treat serious CNS diseases, including schizophrenia, depression and Parkinson's disease.

    From 2002 through 2005, Mr. Bacha launched Inimex Pharmaceuticals as President and Founding Chief Executive Officer, securing more than $35 million in grant and venture capital financing.

    Prior to 2002, Mr. Bacha served as Vice President, Corporate Development of Inflazyme Pharmaceuticals Ltd., was a founding Board member of Urigen Holdings Inc., and was founding CFO and Vice President, Corporate Development of XBiotech Inc.

    Mr. Bacha was also Senior Manager and Director of KPMG's U.S. Health Ventures and Life Sciences Corporate Finance Group in San Francisco. He is currently President and CEO of DelMar Pharmaceuticals, Inc.

    Go back

      Company History

      Sernova was founded in 2006 - London, Ontario;


      2006

      On September 20, the Company announced it had received TSX Venture Exchange approval to change its name to Sernova Corp.


      2005

      In April the Board of Directors brought in a new management team to find viable research and development projects suitable for the Company. On May 16, 2006 the Company announced it had closed a joint venture agreement with Sertonex Inc., a private medical research company based in London Ontario, and Sertoli Technology Inc., a private intellectual property company based in Tucson Arizona. The joint venture allows the Company to own the exclusive rights to the research efforts and intellectual property related to a potential breakthrough treatment for diabetes. That project is now the Company's main focus.


      2004

      On May 4th, Pheromone Sciences Corp announced the conclusion of negotiations with HealthWatchSystems, Inc. of Sarasota, Florida for the sale of all patents, intellectual property and supplies related to the Fertility Monitor. At the company's annual and special shareholder meeting on August 25, 2004, the sale was accepted by the shareholders and the asset sale agreement was then closed on August 31, 2004. The monitor is now sold under the name OV-Watch and Sernova receives royalties on the net sales.


      2000

      In February, through a Share Exchange Agreement, PCS was acquired by Mecca Medi-Tech Inc. (MEC), a venture capital pool company trading on the Canadian Venture Exchange. The combined new entity was named Pheromone Sciences Corporation.

      Pheromone Sciences first commercial product brought to market was the PSC Fertility Monitor. The monitor set a new benchmark in family planning and provides a more reliable and user-friendly approach to natural, cycle-based fertility status measurement. The PSC Fertility Monitor is a non-invasive method of predicting ovulation and the fertile window of women through the measurements of sweat ion changes on the surface of the skin. It is a small wristwatch-like device, containing an interactive microprocessor combined with a biochemical sensor allowing it to produce data that predicts the fertility status of the user (not-fertile, fertile or ovulating). The computed results can then be viewed on the LCD screen of the device and/or the user can be alerted via optional audio signals.


      1997

      PCS succeeded in characterizing a human (female) pheromone, naming it PSC Synchronin.


      1992

      Pheromone Sciences Corporation (PCS) was a private corporation founded by Doug Marett, M.Sc. in 1992.